

GENOMICS | DIAGNOSTIC TESTS | GENETICS | R&D

Genomic Vision chosen for the new EnterNext[®] PEA-PME 150 index

Bagneux (France) - Genomic Vision (FR0011799907 – GV / PEA-PME eligible), a molecular diagnostics company that specializes in the development of diagnostic tests for genetic diseases and cancers using the DNA molecular combing process, announces that it has been chosen to be included in the EnterNext[®] PEA-PME 150 index, launched today.

This new index consists of 150 French companies covered by EnterNext, listed on Euronext and Alternext markets in Paris and among the 80% most liquid shares eligible for PEA-PME accounts. Shares are ranked by the size of their free float.

The weighting of each company is capped at 2.5% and the weighting of each sector at 20%. The index, whose current composition can be found on the [Euronext website](#), will be revised once a year and its weighting will be reviewed every quarter.

This index provides investors with a benchmark of the stock-market performances of the most liquid French small and mid-caps.

Aaron Bensimon, Genomic Vision's co-founder and Chairman, comments: *"We are delighted to have been chosen to be included in this new index within the Euronext PEA-PME index family. Being one of the 150 most liquid French shares just seven months after our IPO illustrates the level of investor interest in Genomic Vision shares. Thanks to our inclusion in this new index, we will be able to benefit from even greater visibility within the financial community in France."*

Next financial press release

- 2014 annual revenue, on January 15, 2015* (after market)

* *Indicative date, subject to potential modifications*

•••

ABOUT GENOMIC VISION

A spinoff of the Institut Pasteur, Genomic Vision is a molecular diagnostics company specialized in developing diagnostic tests for genetic diseases and cancers. Using "molecular combing", an innovative technology that allows the direct visualization of individual DNA molecules, Genomic Vision detects quantitative and qualitative variations in the genome that are at the origin of numerous serious pathologies. Having benefited from the financial support of the Institut Pasteur, SGAM AI, Vesalius Biocapital and Quest Diagnostics, the Company is developing a solid portfolio of tests that notably target breast cancer and cancer of the colon. Since 2013, the Company has marketed the CombHeliX FSHD test for identifying a myopathy that is difficult to detect, Facio-scapulo-humeral dystrophy (FSHD), in the United States thanks

to a strategic alliance with Quest Diagnostics, the American leader in diagnostic laboratory tests, and in France.

ABOUT MOLECULAR COMBING

DNA molecular combing technology considerably improves the structural and functional analysis of DNA molecules. DNA fibers are stretched out on glass slides, as if "combed", and uniformly aligned over the whole surface. It is then possible to identify genetic anomalies by locating genes or specific sequences in a patient's genome using genetic markers, an approach developed by Genomic Vision and patented under the name Genomic Morse Code. This exploration of the entire genome at high resolution via a simple analysis enables the direct visualization of genetic anomalies that are undetectable by other technologies.

For further information, please go to www.genomicvision.com

CONTACTS

Genomic Vision

Aaron Bensimon
Co-founder, Chairman & CEO
Tel.: +33 1 49 08 07 50
investisseurs@genomicvision.com



NewCap

Investor Relations / Strategic Communications
Dušan Orešanský / Emmanuel Huynh
Tel.: +33 1 44 71 94 92
gv@newcap.fr



DISCLAIMER

This press release contains certain forward-looking statements concerning Genomic Vision and its business. Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the prospectus on which the French Financial Market Authority (AMF) granted its visa n° 14-087 on March 19, 2014 and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for GENOMIC VISION shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.